

Drug and Therapeutics Committee – Minutes –Confirmed

Date / Time	Thursday 8 th June 2017
Venue	The Board Room, Alderson House, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes

Attendance

Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG)
Mr K McCorry, Medicines Management, East Riding
Dr O Ogunbambi, Consultant Rheumatologist
Dr F Umerah, Consultant Anaesthetist
Mr P O'Brien, Deputy Chief Pharmacist
Dr A Samson, Infectious Diseases Consultant

Apologies

Prof A Morice, Chair, Professor of Respiratory Medicine
Dr H Klonin, Consultant Paediatrician
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics
Mrs Sue Phillips, Lay Representative

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.06.01	Apologies	As Above.					
2017.06.02	Declarations of Interest	None.					
2017.06.03	Minutes of the previous meeting	The minutes were accepted as a true record.					6/17
2017.06.04	D&T Attendance 16-17	Report accepted with the amendments: Dr A Samson – name to be corrected. State “started April/17”. Dr E Williamson – to be added, prior to Dr Samson, with leaving date. K McCorry – April & July/16 – Sent deputy (EL) – change to orange.	Report accepted with amendments.	SG to amend	SG	7/17	
2017.06.05	D&T Product Requests 16-17	Report accepted with the amendments: Relvar should be RED, making number red 32, number green 1.	Report accepted with amendments.	SG to amend	SG	7/17	
2017.06.06	Action Tracker	<p>Bisphosphonates as supportive therapy for Breast Cancer ML had feedback that there is a meeting due to take place tomorrow and this will be discussed - ongoing.</p> <p>Daclizumab (Zinbryta) SC Pre-filled Injection - Dr James Harley AM to write to applicants.</p> <p>Brivaracetam (Briviact) - Dr A Ming There were concerns about how patients would be initiated, monitored and followed up to assess for effectiveness. AM would write to Dr Ming to clarify his planned arrangements.</p> <p>Obeticholic Acid (Ocaliva) Capsules - Dr Lynsey Corless JM tried to clarify commissioning arrangements with POB. Due to the general election, NHSE had put issuing their position on hold.</p> <p>NICE Guidance April 2017</p>	<p>Ongoing</p> <p>Action Complete</p> <p>Action Complete</p> <p>Ongoing</p>	<p>Await feedback from meeting.</p> <p>POB to clarify commissioning arrangements</p>	<p>ML</p> <p>POB</p>	<p>5/17</p> <p>7/17</p>	<p>6/17</p> <p>6/17</p>

		<p>Ixekizumab for treating moderate to severe plaque psoriasis Non-formulary, application needed. AM to write to Dr Zaman.</p> <p>Valproate and neurodevelopmental disorders: new alert asking for patient review and further consideration of risk minimisation measures Added to HERPC agenda.</p> <p>Ponatinib (Iclusig ▼): risk of vascular occlusive events— updated advice on possible dose reduction Haematology to be informed. AM to write to Dr S Ali.</p> <p>Unconfirmed Minutes from HERPC – 22/03/17 Fluticasone furoate and vilanterol (Relvar Ellipta) - Should be RED status, as only approved by D&TC for DOT. Dr Smith - to be changed to Mr Smith. SG had amended the minutes</p> <p>Dr Hammersley – dexamphetamine SG had added to HERPC agenda and circulated the letters.</p> <p>Fluticasone furoate and Vilanterol(Relvar Ellipta) POB to discuss and clarify commissioning DOT with respiratory service manager. Correspondence from Asthma team is that they would prefer to use Relvar than Symbicort. On agenda for discussion at HERPC.</p> <p>Stalevo & Generics AM to send KMcC the letter received from Dr Ming</p> <p>Paediatric Growth Hormone DC to invite Chris Wood to attend HERPC to discuss further.</p>	Ongoing	AM to write to Dr R Zaman	AM	7/17	
			Action Complete				6/17
			Action Complete				6/17
			Action Complete				6/17
			Action Complete				6/17
			Ongoing	POB to ask service manager	POB	6/17	
			Action Complete				6/17
			Action Complete				6/17
			DC not present, update next time	Ongoing	DC	5/17	
2017.06.07	Correspondence Received	Imuderm cream - Pharmacy Comparison See New Product Request below.	Noted				6/17
2017.06.08	New Product Requests	Levofloxacin – Dr G Barlow – reinstatement on formulary SPG highlighted the key points made in Dr Barlow's letter. This is not likely to be used a great deal, and is a good alternative in highly selected patients. It would still be an Alert Agent and Infection	Put back on formulary as RED & alert drug.	SG to add to formulary	SG	7/17	

		<p>Consultant approval will still be needed, unless prescribed by a Respiratory Consultant when ciprofloxacin or moxifloxacin were deemed clinically inappropriate. ACAT had approved this at the 09/05/17 meeting. There was discussion about HERPC RAG status, with a view that RED was likely to be best. KMcC was asked to check how much was currently prescribed in primary care, if any.</p> <p>Desmopressin Acetate lyophilisate (Noqdirna) - Mr S Kraus The committee felt that there was generally a lack of good data, with most studies against placebo. Only one study tested the melt formulation against tablets. It was felt that initially there might be a risk of hyponatremia, particularly for patients over 65 years. HEY do not widely prescribe this drug, but it was felt that this should be a RED drug for six months, and that an audit should be done to assess efficacy and any reduction in sodium levels for patients. Await plan from Urology, before commencing use.</p> <p>Imuderm cream - Dr R Zaman There were no clinical evidence papers submitted with this application, although the formulary already contains urea-containing emollients. Therefore a comparison table was prepared by Pharmacy Medicines Information. This showed Imuderm cream to be the cheapest agent in class. However, from the request form, it was not clear which product(s) it would replace on the current formulary. ML to write to Dr Zaman to clarify what they want this to replace.</p>	<p>Check current primary care usage.</p> <p>Approved, but ML to write to Mr Kraus re RED status. Monitor sodium levels and audit efficacy/side effects for 6 months.</p> <p>Deferred, to clarify what this will replace on the existing formulary.</p>	<p>KMcC to provide figures</p> <p>ML to write to Mr Kraus</p> <p>ML to write to Dr Zaman</p>	<p>KMcC</p> <p>ML</p> <p>ML</p>	<p>7/17</p> <p>7/17</p> <p>7/17</p>	
2017.06.09	NICE Guidance	<p>May 2017</p> <p>Eating disorders: recognition and treatment https://www.nice.org.uk/guidance/ng69</p> <p>Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) https://www.nice.org.uk/guidance/ta444</p> <p>Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs https://www.nice.org.uk/guidance/ta445</p> <p>Type 2 diabetes in adults: management</p>	<p>Noted</p> <p>Not used at HEY for this.</p> <p>Already on formulary for Rheumatology</p> <p>Noted</p>	<p>No further Action</p> <p>No further Action</p> <p>No further Action</p> <p>No further</p>		<p>6/17</p> <p>6/17</p> <p>6/17</p> <p>6/17</p>	

		https://www.nice.org.uk/guidance/ng28 Vitamin D: increasing supplement use in at-risk groups https://www.nice.org.uk/guidance/ph56 Intravenous fluid therapy in adults in hospital https://www.nice.org.uk/guidance/cg174 Idiopathic pulmonary fibrosis in adults: diagnosis and management https://www.nice.org.uk/guidance/cg163 Hip fracture: management https://www.nice.org.uk/guidance/cg124	Noted	Action				6/17
			Noted	No further Action				6/17
			Noted	No further Action				6/17
			Noted	No further Action				6/17
2017.06.10	MHRA Drug Safety update	May 2017 Finasteride: rare reports of depression and suicidal thoughts. Propecia is not used at HEY.	Noted	No further Action				6/17
2017.06.11	Minutes from the Safe Medication Practice Committee	Wednesday 5th April 2017	Noted	No further Action				6/17
2017.06.12	Minutes from the Hull and East Riding Prescribing Committee	None						6/17
2017.06.13	Guidelines	Anticoagulation Prescribing Guidance This guidance poster had been updated regarding use of fondaparinux for the treatment of Acute Coronary Syndrome (ACS). This was in line with NICE CG94: Unstable angina and NSTEMI: early management. The poster has been developed by Pharmacy and Cardiology, and had previously been discussed and approved at Thrombosis Committee. As previously, the poster will be put up on wards and posted on the Trust intranet. The manufacturer of fondaparinux was assisting the Trust by providing training to medical, nursing and pharmacy staff in key usage areas.	Approved. It was thought that it would be helpful to share the poster with new Doctors.	POB to liaise with Yvonne (Senior Pharmacist - Cardiology)	POB	7/17		
2017.06.14	Chairs Approvals	Gamma Interferon – Dr C. Hall - cerebral aspergillosis.	Noted	No further action				6/17

2017.06.15	Issues to escalate to Operational Quality Committee	None.					6/17
2017.06.16	Any Other Business	ML asked about two new product requests: 1) Akynzeo 2) Ibrance patient access scheme New product request forms were being completed and would be brought to the committee once the fully completed form and evidence was received.	Should be discussed at D&TC next month.	ML to liaise with Oncology colleagues to send applications to SPG	ML	7/17	
2017.06.17	Date and Time of Next Meeting	Date – Thursday 13th July 2017 Time – 8.15am-9.30am Venue – Board Room, Alderson House, HRI					